PBM:NASDAQPsyence Biomedical Ltd. Analysis

Price sits at $3.16, comfortably above the 20‑day SMA of $2.98 but well under the 50‑day SMA of $3.68 and dramatically below the 200‑day SMA of $33.77, signaling a long‑term bearish bias. The RSI at 48 is neutral and the MACD histogram is positive with a bullish signal, while the stock trades between a support of $2.62 and resistance of $3.28. Volume is increasing, yet the 30‑day volatility of 63% and a computed beta above 4 indicate extreme price swings. Fundamentally, the company reports zero revenue, a negative EBITDA of $6.2 M, and operating cash outflows of $8.1 M, reflecting a pre‑revenue biotech dependent on cash reserves. Cash on hand (~$7.4 M) barely exceeds the market cap (~$12 M), and a price‑to‑book of 0.43 suggests a low valuation relative to assets. No dividend is paid, and both ROE and ROA are deeply negative, with a historic max drawdown of –99.5%, underscoring financial fragility. Regulatory risk is high as the lead candidate remains in Phase IIb, and the sector’s inherent uncertainty amplifies the overall risk profile. Despite these challenges, the modest cash cushion and cheap book value provide a speculative upside if clinical milestones are met, supporting a long‑term buy view while short‑term bias remains bearish.